A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men

Sexually Transmitted Diseases

Volumn 34, Issue 8, 2007, Pages 545-552

  Stamm, Walter E ^a   Batteiger, Byron E ^b   McCormack, William M ^c   Totten, Patricia A ^a   Sternlicht, Andrew ^d   Kivel, Nancy M ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INDIANA UNIVERSITY   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d ActivBiotics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZITHROMYCIN; PLACEBO; RIFALAZIL;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTALLURIA; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA GENITALIUM; NAUSEA; NEISSERIA GONORRHOEAE; NONSPECIFIC URETHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; UREAPLASMA UREALYTICUM;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MYCOPLASMA GENITALIUM; MYCOPLASMA INFECTIONS; RIFAMYCINS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TREATMENT OUTCOME; UREAPLASMA INFECTIONS; UREAPLASMA UREALYTICUM; URETHRITIS;

EID: 34547638218     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000253348.44308.8c     Document Type: Article

References (22)

1. Peipert JF. Genital chlamydial infections. N Engl J Med 2003; 349:2424-2430.
2. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
3. Totten PA, Schwartz MA, Sjostrom KE, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001; 183:269-276.
4. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Morb Mortal Wkly Rep 2006; 51 (No. RR-11).
5. Stamm WE. Chlamydia trachomatis: The persistent pathogen. Sex Transm Dis 2001; 28:684-689.
6. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double blind study. JAMA 1995; 274:545-549.
7. Fujii K, Tsuji A, Miyazaki S, et al. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother 1994; 38:1118-1122.
8. Suchland RJ, Bourillon A, Denamur E, et al. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother 2005; 49:1120-1126.
9. Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45:1972-1976.
10. Chen Y-X, Cabana B, Kivel N, et al. Escalating single-dose safety and pharmacokinetics of rifalazil in healthy volunteers. AAPS J 2004; 6:M1103.
11. Wood JC, Lu RM, Peterson EM, et al. Evaluation of Mycotrim-GU for isolation of Mycoplasma species and Ureaplasma urealyticum. J Clin Microbiol 1985; 22:789-792.
12. Broitman NL, Floyd CM, Johnson CA, et al. Comparison of commercially available media for detection and isolation of Ureaplasma urealyticum and Mycoplasma hominis. J Clin Microbiol 1992; 30:1335-1337.
13. Dutro SM, Hebb JK, Garin CA, et al. Development and performance of a microwell-plate-based polymerase chain reaction assay for Mycoplasma genitalium. Sex Transm Dis 2003; 30:756-763.
14. Mor N, Simon B, Heifets L. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrob Agents Chemother 1996; 40:1482-1485.
15. Farquhar R, Xia M, Meerts I, et al. Activity of novel rifamycins in assays for human cytochrome p450 induction. In Abstracts- 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA; 2005. Abstract F-2048.
16. Chen Y-X, Cabana B, Kivel N, et al. Effect of rifalazil on the pharmacokinetics of ethinyl estradiol in healthy post-menopausal women. AAPS J 2005; 7:47.
17. Mae T, Hosoe K, Fujii K, et al. In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica 1996; 26:793-802.
18. Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003; 47:1135-1136.
19. Suchland RJ, Brown K, Rothstein DM, et al. Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection. Antimicrob Agents Chemother. 2006; 50:439-444.
20. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992; 327:921-925.
21. Jensen JS. Mycoplasma genitalium: The aetological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol 2004; 18:1-11.
22. Gaurivaud P, Laigret F, Bove J-M. Insusceptibility of members of the class Mollicutes to Rifampin: Studies of the Spiroplasma citri RNA polymerase B-subunit gene. Antimicrob Agents Chemother 1996; 40:858-862.